BridgeBio Pharma (BBIO) has priced its initial public offering of 20.5M common shares at $17.
Underwriters over-allotment is an additional 3.075M common stock.
The shares are expected to begin trading on the Nasdaq on June 27 under the ticker symbol “BBIO”
Closing date is July 1.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.